Scientists at Jackson Laboratory developed a novel antibody therapy that provides broad protection against diverse influenza A virus strains, including those with pandemic potential, by targeting conserved viral matrix protein epitopes. Unlike traditional neutralizing antibodies, this therapy employs nonneutralizing antibodies that tag infected lung cells to recruit immune clearance, thus preventing viral escape. The treatment demonstrates an extended window of efficacy and could fundamentally shift influenza therapy and pandemic preparedness.